<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30082489</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1549-490X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>23</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>The oncologist</Title>                <ISOAbbreviation>Oncologist</ISOAbbreviation>            </Journal>            <ArticleTitle>Pretreatment <sup>18</sup>F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>1144-1152</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2018-0001</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Intratumoral heterogeneity of <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) uptake in primary tumor has proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intraindividual heterogeneity in metastatic diseases remains unknown. The aim of this study was to evaluate pretreatment positron emission tomography/computed tomography (PET/CT) <sup>18</sup>F-FDG-based heterogeneity for the prediction of first-line treatment outcome in metastatic triple-negative breast cancer (mTNBC).</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">mTNBC patients from three clinical trials (NCT00601159, NCT01287624, and NCT02341911) with whole-body <sup>18</sup>F-FDG PET/CT scan before first-line gemcitabine/platinum were included. Heterogeneity index (HI) and the maximum of FDG uptake (MAX) across total metastatic lesions (-T) on baseline PET/CT scans were assessed. HI was measured by MAX divided by the minimum FDG uptake across metastatic lesions. Optimal cutoffs were determined by time-dependent receiver operator characteristics (ROC) analysis. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared by log-rank test.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 42 mTNBC patients were included in this study. The median PFS of patients with high HI-T (&gt;1.9) and high MAX-T (&gt;10.5) was significantly shorter than patients with low HI-T (&lt;1.9; <i>p</i> = .049) and low MAX-T (&lt;10.5; <i>p</i> = .001). In terms of OS, only high MAX-T was significant for poorer outcome (<i>p</i> = .013). ROC curve analysis confirmed the predictive value of MAX and HI in mTNBC patients. Area under the ROC curve for MAX-T and HI-T was 0.75 and 0.65, indicating a higher predictive accuracy than conventional clinical risk factors.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">HI and MAX measured among metastatic lesions on pretreatment <sup>18</sup>F-FDG PET/CT scans could be potential predicators for first-line treatment outcome in patients with mTNBC.</AbstractText>                <AbstractText Label="IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">Intratumoral heterogeneity of <sup>18</sup>F-fluorodeoxyglucose (FDG) uptake in primary tumor has proven to be a robust surrogate predictive marker. A novel positron emission tomography/computed tomography (PET/CT) parameter-heterogeneity index (HI) to quantify the heterogeneous characteristics of metastatic disease is proposed. Triple-negative breast cancer (TNBC) is a highly heterogeneous disease and remains a clinical challenge. The predictive performance of HI, along with the maximum FDG uptake (MAX), measured on pretreatment PET/CT scans in patients with metastatic TNBC was evaluated. Results indicate that HI and MAX may serve as applicable imaging predicators for treatment outcome of metastatic TNBC in clinical practice.</AbstractText>                <CopyrightInformation>© AlphaMed Press 2018.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gong</LastName>                    <ForeName>Chengcheng</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ma</LastName>                    <ForeName>Guang</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Biomedical Imaging, Fudan University, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Xichun</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Yingjian</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Biomedical Imaging, Fudan University, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Zhonghua</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Jian</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Yannan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Yi</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Yizhao</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Zhongyi</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China yangzhongyi21@163.com pro_wangbiyun@163.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Biomedical Imaging, Fudan University, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Biyun</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China yangzhongyi21@163.com pro_wangbiyun@163.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Shanghai Medical College, Shanghai, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>06</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncologist</MedlineTA>            <NlmUniqueID>9607837</NlmUniqueID>            <ISSNLinking>1083-7159</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">18F‐fluorodeoxyglucose positron emission tomography/computed tomography</Keyword>            <Keyword MajorTopicYN="Y">Genetic heterogeneity</Keyword>            <Keyword MajorTopicYN="Y">Metastatic breast cancer</Keyword>            <Keyword MajorTopicYN="Y">Prognosis</Keyword>            <Keyword MajorTopicYN="Y">Triple‐negative breast neoplasms </Keyword>        </KeywordList>        <CoiStatement>Disclosures of potential conflicts of interest may be found at the end of this article.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>04</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>04</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30082489</ArticleId>            <ArticleId IdType="pii">theoncologist.2018-0001</ArticleId>            <ArticleId IdType="doi">10.1634/theoncologist.2018-0001</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>